naa a22 4500 510763863 CHVBK 20180411083149.0 cr unu---uuuuu 180411e20131001xx s 000 0 eng 10.1007/s12094-013-1013-5 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1013-5 Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis [Elektronische Daten] [Z. Song, L. Shao, B. Lin, Y. Zhang] Objective: This retrospective analysis evaluates the clinical outcomes of extensive-stage small cell lung cancer (SCLC) patients who received second-line chemotherapy after platinum-based first-line chemotherapy, especially focusing on efficacy and toxicity between single-agent and combination chemotherapy. Methods: We retrospectively reviewed 193 patients who received second-line chemotherapy for extensive-stage SCLC. Patients relapsing or progressing beyond 90days were defined as sensitive recurrence patients, and below 90days as refractory recurrence patients. Survival curves were plotted using the Kaplan-Meier method. The Cox proportional hazard model was used for multivariate analysis. Results: 138 patients received combination chemotherapy and 55 received single-agent treatment. The objective response rate (ORR) was 25.4% in the combination group and 9.1% in the single-agent group (p=0.012). The disease control rate (DCR) was 65.2 and 34.5%, respectively, (p<0.001). The progression-free survival (PFS) was 3.80months in the combination group and 2.13months in the single-agent group (p=0.001). In the sensitive recurrence group, the median PFS was 3.80months in combination group and 3.23months in single-agent group (p=0.092). In the refractory recurrence group, the median PFS was 2.83 and 1.30months, respectively (p=0.001). The grade III/IV toxicity in single-agent group is much lower than the combination group (56.4 vs. 74.6%, p=0.013). Conclusion: Our retrospective data suggest a potential role of prolonging the PFS for combination treatment in extensive-stage SCLC second-line treatment, especially for the refractory recurrence patients, but with more toxicity as compared to single-agent. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Small cell lung cancer nationallicence Second-line nationallicence Monotherapy nationallicence Combination nationallicence Efficacy nationallicence Song Z. Department of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road, 310022, Hangzhou, People's Republic of China aut Shao L. Department of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road, 310022, Hangzhou, People's Republic of China aut Lin B. Department of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road, 310022, Hangzhou, People's Republic of China aut Zhang Y. Department of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road, 310022, Hangzhou, People's Republic of China aut Clinical and Translational Oncology Springer Milan 15/10(2013-10-01), 843-848 1699-048X 15:10<843 2013 15 12094 https://doi.org/10.1007/s12094-013-1013-5 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1013-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Song Z. Department of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road, 310022, Hangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Shao L. Department of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road, 310022, Hangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Lin B. Department of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road, 310022, Hangzhou, People's Republic of China aut NATIONALLICENCE 700 1- Zhang Y. Department of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road, 310022, Hangzhou, People's Republic of China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/10(2013-10-01), 843-848 1699-048X 15:10<843 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer